In 2018, these 14 researchers of the DZHK will be among the one percent of the most cited scientists worldwide. This is the result of Clarivate Analytics' list of "Highly Cited Researchers":
Scientists at the German Centre for Cardiovascular Research (DZHK) were the first to show that Empagliflozin, a diabetes drug, directly affects the human heart muscle and improves heart function. The results provide hope for the treatment of heart failure with preserved pump...
The Medical Faculty of the Ludwig Maximilian University (LMU) Munich is supporting young doctors to carry out medical research by expanding its clinical research and training program to include vascular research. The LMU and the University Hospital of Munich are partner...
The German Centre for Cardiovascular Research (DZHK) has received a donation of €400,000 to fund a research position that will study cardiac genetics at the Children's Heart Center of Kiel University Hospital in Schleswig-Holstein (UKSH).
A new study from the German Centre for Cardiovascular Research (DZHK) is investigating whether a known drug could bring hope to the millions of people living with heart failure. There is currently no cure for some forms of heart failure and doctors can only treat the symptoms and...
Why do heart disease and stroke so often occur together? How can the care of people who have heart attack following a stroke be improved? Neurologists and cardiologists are investigating this in the PRAISE study. This study is conducted under the direction of Charité -...
The German Centre for Cardiovascular Research (DZHK) is hosting a global meeting of world leading scientists to answer the question: How can the benefits of medical research reach the patient?
There are two new junior research groups at the German Centre for Cardiovascular Research (DZHK). The DZHK was able to successfully recruit their leaders from the US: Dr. Nuno Guimarães Camboa previously carried out research at the University of California and is now coming to...
Jeanette Erdmann (DZHK partner site Hamburg/Kiel/Lübeck), Michael Joner and Heribert Schunkert (both DZHK partner site Munich) are members of a consortium which is supported by the French-American Leducq Foundation with six million dollars.
If several coronary vessels are dangerously narrowed, patients are often treated with a bypass operation. In other words, vascular grafts are fashioned that redirect vital oxygenated blood around the blocked sections to the heart. The patients’ veins are often used as bypass...
